Cathal Friel talks to Zak Mir about ‘sleeping giant’ hVIVO #HVO , and his plans for the new enlarged Open Orphan #ORPH
RNS Number: 2129 A AIM 20 January 2020 NOTICE. NOTICE OF CANCELLATION OF ADMISSION TO TRADING ON AIM- XLON. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
Cathal Friel, CEO of Open Orphan #ORPH announces that the hVIVO deal is finally in the bag and tells Proactive London what the timeline for shareholders now looks like. Cathal also provides some news on the Genomic Database and explains how he expects hVIVO #HVO to make a profit.
RNS Number: 6532 Z hVIVO plc 17 January 2020 hVIVO plc. In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,664,276 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury.
Open Orphan #ORPH announces that the hVIVO #HVO merger offer is now wholly unconditional. Ordinary & consideration shares combined total 445,622,374, & will start trading on Jan 20
RNS Number: 3414 Z hVIVO plc 15 January 2020 hVIVO plc. In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,599,062 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury.
Open Orphan #ORPH announces the 2nd closing of the hVIVO_UK #HVO offer. There will be no extension. As at 1pm Jan 13th, valid acceptances received for 77,348,100 hVIVO shares (approx 92.5%)
London, UK, 13 January 2020: hVIVO plc, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 27,273 new...
London, UK, 13 January 2020: hVIVO plc, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 37,941 new...
RNS Number: 0610 Z hVIVO plc 13 January 2020 hVIVO plc. In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,583,946 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury.
London, UK, 09 January 2020: hVIVO plc, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 15,116 new...
London, UK, 8 January 2020: hVIVO plc, an industry leading clinical development services business pioneering human disease models based upon viral and allergen challenge, announces that, application has been made to AIM for the admission of 30,602 new ordinary shares of 5.0 p each in the Company.. The New Ordinary Shares have been allotted pursuant to the...
London, UK, 08 January 2020: hVIVO plc, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 131,465 new...
RNS Number: 9043 Y hVIVO plc 06 January 2020 hVIVO plc. Notification pursuant to AIM Rule 41. Proposed cancellation of trading on AIM.
#ORPH Open Orphan offer for hVIVO_UK #HVO now unconditional. CEO Cathal Friel ‘pleased with the strong level of acceptances which reinforces our view that this is a good deal for the shareholders of both companies'
RNS Number: 5284 X hVIVO plc 27 December 2019 hVIVO plc. In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,421,879 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury.
London, UK, 19 December 2019: hVIVO plc, an industry leading clinical development services business supporting product development for companies developing antivirals, vaccines and respiratory therapeutics, announces that, following the exercise of employee share options by an ex-employee, application has been made to AIM for the admission of 2,500 new...
Form 8.3 - Link Fund Solutions Ltd:HVIVO PLC.
RNS Number: 2303 X hVIVO plc 19 December 2019 hVIVO plc. In accordance with Rule 2.9 of the City Code on takeovers and Mergers, the Company confirms that, as at the date of this announcement, it had 83,419,379 ordinary shares of 5 pence each in issue. The Company holds no ordinary shares in treasury.
Andrew Hore Quoted Micro 16 December 2019 #CFCP #SuINOx #ASH #PRIM #GGP #GUN #NQMI #HYDP #TTAU #ESO #NTLP #FRM #GTLY #NWF #PTRO #VNET #VRS #ORPH #HVO #SKIN #TUNE #DMTR #SRO #CRU #FA #RBN #TPX #WPHO #KOOV #ADT1 #SEFA #ZEN #HWSL #FAR #smallcaps #microcaps
hVIVO Plc
HVO.L
hVIVO Plc
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    82.30M
Watchlist